Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF	: CH
obligations may continue. See		

ANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Huang James					2. Issuer Name and Ticker or Trading Symbol WINDTREE THERAPEUTICS INC /DE/ [Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last)		irst)	(Middle)			INT]	•							X Director Officer (below)				er (spe	
C/O WII		HERAPEUTICS D, SUITE 100	,			Date of 1/24/20		Trans	saction ((Month	/Day/Year)								
				_ 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WARRIN	NGTON P.	A	18976		_										,	One Repo	•		ng
(City)	(5	State)	(Zip)																
		Tal	ole I - N	on-Der	ivativ	e Se	curitie	s Ac	quire	d, Di	sposed o	f, or Be	neficial	ly Owned					
		Date		Exe r) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Ownership			
									Code	v	Amount	(A) or (D)	Price	Reported Transaction(s (Instr. 3 and 4				(Instr. 4	4)
Common Stock												4,527,345		I		Via Panacea Venture Healthcare Fund I L.P. ⁽¹⁾			
Common Stock													114,41	I		(HK) Const	ulting igement pany		
			Table II								posed of,			Owned		,			
Derivative Conversion Date Execuse Security or Exercise (Month/Day/Year) if any		3A. Deer Execution if any (Month/E	med 4. on Date, Transact Code (In		ction				Exerci	sable and te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derive Secu Bene Owne Follo Repo Trans	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. 11. Natu of Indire Benefici Ownersh (I) (I) (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (Right to	\$4.32	04/24/2019			A		60,000		12/21/2	019 ⁽²⁾	04/24/2029	Common Stock	60,000	\$0	6	0,000	D		

Explanation of Responses:

- 1. The Reporting Person is Director of Panacea Venture Healthcare Fund I L.P. The Reporting Person disclaims beneficial ownership of the shares held by the fund, except to the extent of his pecuniary interest
- 2. This stock option shall vest in a series of three successive, equal installments measured from the date of Mr. Huang's appointment to the Board of Directors on December 21, 2018.

/s/ Mary B. Templeton, Esq., as 04/26/2019 Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.